Neogenomics Inc
Change company Symbol lookup
Select an option...
NEO Neogenomics Inc
VIVC Vivic Corp
BAC Bank of America Corp
CMSQF Computershare Ltd
UNH UnitedHealth Group Inc
RYAAY Ryanair Holdings PLC
FNGO MicroSectors? FANG+? Index 2X Leveraged ETN
LAD Lithia Motors Inc
SBUX Starbucks Corp
HYLN Hyliion Holdings Corp
Go

Health Care : Life Sciences Tools & Services | Small Cap Growth
Company profile

NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee. It offers testing services, which include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC), Molecular testing and Pathology consultation. Its Pharma Services and Clinical Trials group provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.

Closing Price
$39.23
Day's Change
-2.12 (-5.13%)
Bid
--
Ask
--
B/A Size
--
Day's High
41.17
Day's Low
38.79
Volume
(Below Average)
Volume:
589,081

10-day average volume:
680,923
589,081

Company Profile

NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee. It offers testing services, which include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC), Molecular testing and Pathology consultation. Its Pharma Services and Clinical Trials group provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
10.24x
Price/Book (MRQ)
6.54x
Price/Cash Flow (TTM)
151.60x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

October 2020
Current Month
4.3M
Previous Month
4.0M
Percent of Float
4.06%
Days to Cover
7.8125 Days

Share Information

NEO is in a share class of common stock
Float
105.3M
Shares Outstanding
111.0M
Institutions Holding Shares
367
91.80%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Douglas M. VanOortChmn.
  • George A. CardozaPres.
  • Kathryn B. McKenzieCFO
  • Robert J. ShovlinCorp.Exec.
  • Cynthia DieterCAO

Address

Insider Trading

During the most recent quarter, 210K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.